Ohio Couple’s Xarelto Lawsuit Adds To Common Allegations In MDL

July 01, 2016 – – TheProductLawyers.com offers insight on one of the most recent cases to join the multidistrict litigation (MDL) 2592 against Xarelto and its manufacturers—Bayer AG and Janssen Pharmaceuticals (a branch of Johnson & Johnson Corporation). Originally filed in Ohio by a husband and wife, the lawsuit alleges that the anticoagulant is directly linked to an uncontrolled intestinal bleeding event the woman suffered.

The U.S. Food and Drug Administration (FDA) approved the new-generation anticoagulant drug in 2011. While it was initially hailed as a breakthrough in the prevention of dangerous blood clots, public opinion has since shifted. Originally, Xarelto was approved to treat those who suffered from pulmonary embolism or deep vein thrombosis and as a clot preventative in individuals recovering from hip or knee replacement surgeries. Soon after its debut, Xarelto was also approved as part of a preventative treatment of strokes for those with atrial fibrillation. A common cardiac condition, atrial fibrillation can elevate an individual’s risk for strokes.

The Ohio lawsuit claims that the woman began taking Xarelto on the advice of her family physician because she suffered from atrial fibrillation. Only two months after beginning a regimen of the anticoagulant, she suffered a severe intestinal bleed, which necessitated drastic life-saving mitigation. The suit claims that the catastrophic bleeding event, the resulting anemia, and other unnamed side effects have substantially impaired her ability to lead a functional life. Because she requires ongoing medical treatment as a direct result of the intestinal bleeding, the couple is seeking over $150,000 in damages.

As a result of the large number of adverse event reports received by the FDA, the agency has issued two black box warnings against Xarelto. This measure can immediately precede a product recall. There has been a landslide of suits now numbering more than 3,000 nationally, which has been combined into MDL 2592. The MDL represents more than 2,800 plaintiffs who similarly claim that the drug companies placed them at an increased risk for catastrophic bleeding events, and in many cases led directly to harm or death. A similar mass tort program has been consolidated by the Philadelphia Court of Common Pleas and represents 550 individual claims.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011135